Chemokines and their receptors are important elements for the selective attraction of various subsets of leukocytes. To better understand the selective migration of functional subsets of T cells, chemokine receptor expression was analyzed using monoclonal antibodies, RNase protection assays, and the response to distinct chemokines. Naive T cells expressed only CXC chemokine receptor (CXCR)4, whereas the majority of memory/activated T cells expressed CXCR3, and a small proportion expressed CC chemokine receptor (CCR)3 and CCR5. When polarized T cell lines were analyzed, CXCR3 was found to be expressed at high levels on T helper cell (Th)0s and Th1s and at low levels on Th2s. In contrast, CCR3 and CCR4 were found on Th2s. This was confirmed by functional responses: only Th2s responded with an increase in [Ca2+]i to the CCR3 and CCR4 agonists eotaxin and thymus and activation regulated chemokine (TARC), whereas only Th0s and Th1s responded to low concentrations of the CXCR3 agonists IFN-γ–inducible protein 10 (IP-10) and monokine induced by IFN-γ (Mig). Although CCR5 was expressed on both Th1 and Th2 lines, it was absent in several Th2 clones and its expression was markedly influenced by interleukin 2. Chemokine receptor expression and association with Th1 and Th2 phenotypes was affected by other cytokines present during polarization. Transforming growth factor β inhibited CCR3, but enhanced CCR4 and CCR7 expression, whereas interferon α inhibited CCR3 but upregulated CXCR3 and CCR1. These results demonstrate that chemokine receptors are markers of naive and polarized T cell subsets and suggest that flexible programs of chemokine receptor gene expression may control tissue-specific migration of effector T cells.
Skip Nav Destination
Article navigation
16 March 1998
Article|
March 16 1998
Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes
Federica Sallusto,
Federica Sallusto
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Search for other works by this author on:
Danielle Lenig,
Danielle Lenig
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Search for other works by this author on:
Charles R. Mackay,
Charles R. Mackay
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Search for other works by this author on:
Antonio Lanzavecchia
Antonio Lanzavecchia
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Search for other works by this author on:
Federica Sallusto
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Danielle Lenig
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Charles R. Mackay
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Antonio Lanzavecchia
From the *Basel Institute for Immunology, CH-4005, Basel, Switzerland; ‡Leukosite Inc., Cambridge, Massachusetts 02142; and §Millennium Biotherapeutics Inc., Cambridge, Massachusetts 02139
Address correspondence to Federica Sallusto, Basel Institute for Immunology, Grenzacherstrasse 487, CH-4005 Basel, Switzerland. Phone: 41-61-6051348; Fax: 41-61-6051222; E-mail: [email protected]
The Basel Institute for Immunology was founded and is supported by F. Hoffmann–La Roche Ltd., Basel, Switzerland.
The present address of Charles R. Mackay is Millenium Biotherapeutics Inc., Cambridge, MA 02139.
Received:
November 06 1997
Revision Received:
January 13 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 187 (6): 875–883.
Article history
Received:
November 06 1997
Revision Received:
January 13 1998
Citation
Federica Sallusto, Danielle Lenig, Charles R. Mackay, Antonio Lanzavecchia; Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes . J Exp Med 16 March 1998; 187 (6): 875–883. doi: https://doi.org/10.1084/jem.187.6.875
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement